Menin drugs for Relapsed/Refractory Acute Myeloid Leukemia
2 tracked Menin drugs in the Relapsed/Refractory Acute Myeloid Leukemia race. The class explanation lives on the Menin page; the full indication pipeline across every mechanism is on the Relapsed/Refractory Acute Myeloid Leukemia page.
2 approved / phase 4
Head-to-head evidence: Revumenib vs Ziftomenib